| Previous Close | 62.93 |
| Open | 62.92 |
| Bid | 63.37 x 700 |
| Ask | 63.38 x 1100 |
| Day's Range | 62.72 - 63.72 |
| 52 Week Range | 46.01 - 63.72 |
| Volume | 4,173,713 |
| Avg. Volume | 6,587,321 |
| Market Cap | 104.09B |
| Beta | 1.07 |
| PE Ratio (TTM) | 23.18 |
| EPS (TTM) | 2.74 |
| Earnings Date | Oct 26, 2017 |
| Dividend & Yield | 1.56 (2.50%) |
| Ex-Dividend Date | 2017-07-05 |
| 1y Target Est | 58.27 |
- InvestorPlace•2 days ago
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks which is decent but still underwhelming relative to the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) as a whole.Source: A 4 via Flickr
- Motley Fool•2 days ago
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
These next-generation medicines are quickly becoming the foundation for advanced cancer treatments.
- Motley Fool•3 days ago
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
It's a tough decision between these two big pharma stocks.
